glp-1 employer coverage news october 2025 Approaches to Employer FAQs on the Rise
Description
Sjolund K, Sanden G, Hakanson R, Sundler F
No obstante, su uso requiere un seguimiento mdico estricto para prevenir y controlar los posibles efectos adversos
Importantly, despite the evidence for use of SGLT-2 inhibitors for DKD treatment, they should not be used in patients with type 1 diabetes because of the risk of euglycaemic diabetic ketoacidosis
These medications work by mimicking the action of naturally occurring GLP-1 , a hormone released from the intestine in response to food intake
This is literally the same mechanism that GLP-1 medications are activating just from the other direction
